De-escalated radiotherapy for HER2-overexpressing breast cancer patients with 1-3 positive lymph nodes undergoing anti-HER2 targeted therapy

BACKGROUND: In the era of anti-HER2 targeted therapy, the potential clinical feasibility of considering HER2-overexpressing breast cancer cases presenting with 1-3 positive axillary lymph nodes as low-risk, and thereby contemplating postoperative radiotherapy reduction, remains an important subject...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Jing, Huang, Suning, Bi, Zhuofei, Zhang, Xiaoxue, He, Ziqing, Lan, Xiaowen, Tan, Yuting, Lin, Xiao, Zhou, Wenyi, Huang, Xiaobo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10646411/
https://www.ncbi.nlm.nih.gov/pubmed/38023183
http://dx.doi.org/10.3389/fonc.2023.1280900

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10646411/
https://www.ncbi.nlm.nih.gov/pubmed/38023183
http://dx.doi.org/10.3389/fonc.2023.1280900

Ejemplares similares